Kadimastem has raised NIS 15M which will fund clinical and pre-clinical development for cellular therapy; target price unchanged. Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingKadimastem has raised NIS 15M which will fund clinical and pre-clinical development for cellular therapy; target price unchanged.
Cellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged. Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingCellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged.
Kadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85 Post author:jaimeuss_admin Post published:16 בSeptember 2018 Post category:Research Continue ReadingKadimastem offers treatment of diabetes and neurological diseases such as ALS by cellular therapy; Company is pursuing clinical trial (ALS), and pre-clinical processes (diabetes); target price set at NIS 0.85
Cellect. On track with its strategic plans; successfully completed proof of concept for ApoTainerTM; sufficient cash to support clinical and preclinical trials; price target unchanged Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingCellect. On track with its strategic plans; successfully completed proof of concept for ApoTainerTM; sufficient cash to support clinical and preclinical trials; price target unchanged
Cellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9 Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingCellect Biotechnology Ltd.: Significant recently reported findings open the ApoGraft™ platform to also be used in the fat-derived stem cell segment; price target raised to $16.9
Cellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged. Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingCellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged.
Cellect Biotechnology Ltd.: Exposure to the global stem cells industry Post author:jaimeuss_admin Post published:30 בAugust 2018 Post category:Research Continue ReadingCellect Biotechnology Ltd.: Exposure to the global stem cells industry
